AZNAstraZenecaRunning, no new patients
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 736 (final count)
- Started
- Feb 13, 2005
- Main results expected
- Feb 27, 2009
- Fully finished
- Dec 31, 2026
- Results posted
- Jun 15, 2010
What counts as success
The trial's main goal(s), called the “primary outcome.”
Time to Progression (TTP)
Measured over: RECIST(Response Evaluation Criteria in Solid Tumors ) tumour assessments carried out every 12 weeks (+/- 2 weeks) from randomisation for study duration (48 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT00099437 · record last updated 2026-09-14 · checked 2026-11-09 15:47 UTC